This study involved four major activities in estimating the current size of the human microbiome market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Major Growth Driving Factors:
The major factors driving the growth of the market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
Market Size Estimation:
Both top-down and bottom-up approaches were used to estimate and validate the total size of the human microbiome market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
# The key players in the industry and market have been identified through extensive secondary research
# The revenues generated from the human microbiome business of leading players have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Projected Surge in Global Revenue:
The human microbiome market is projected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024. This market is projected to grow at a CAGR of 31.5% over the forecast period. The primary drivers behind the expansion of this industry are the technological advancement in microbiome sequencing, the collaborative efforts between the microbiome industry, organizations, and academia for microbiome research, and the increase in the number of startups and SMEs exploring the microbiome niche, and further opportunities such as the increase in demand for personalized medicine and the emergence of synbiotics may help drive the human microbiome market.
Data Triangulation:
After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition:
The human microbiome refers to a collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that live within and on the human body. These microorganisms interact with each other and with the human host in a complex and dynamic manner, playing important roles in a range of physiological processes, including digestion, immune function, and metabolism. The human microbiome is highly diverse and varies between individuals and different regions of the body. The market encompasses various sectors, including research tools, diagnostics, therapeutics, and consumer products, aimed at leveraging the knowledge and potential of the microbiome to improve human health and well-being.
This includes the development and commercialization of microbiome-based therapies, such as live biotherapeutic products (LBPs), probiotics, prebiotics, and other microbial interventions, as well as the development of diagnostic tools for assessing and monitoring the microbiome.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
Key Players:
The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc. (US), YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics